Glutathione-related mechanisms in cellular resistance to anticancer drugs (Review)

International Journal of Oncology

Volumn 12, Issue 4, 1998, Pages 871-882

  Zhang, Kai ^a   Mack, Peter ^a   Wong, Kim Ping ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Gamma glutamylcysteine synthetase; Glutathione; Glutathione peroxidase; Glutathione reductase; Glutathione S transferases; Inhibition; Modulation; Multidrug resistance; Multidrug resistance associated protein

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BUTHIONINE SULFOXIMINE; CADMIUM; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; LEUKOTRIENE C4; LIPID PEROXIDE; MELPHALAN; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN; PROTEIN KINASE C;

CANCER; DRUG CONJUGATION; DRUG DETOXIFICATION; DRUG RESISTANCE; DRUG TRANSPORT; GENE OVEREXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CARRIER PROTEINS; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HUMANS; MEMBRANE TRANSPORT PROTEINS; METABOLIC DETOXICATION, DRUG; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS;

EID: 0031939392     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (168)

1. Meister A and Anderson ME: Glutathione. Annu Rev Biochem 52: 711-760, 1983.
2. Dulik DM, Fenselau C and Hilton J: Characterization of melphalan-glutathione adducts whose formation is catalysed by glutathione S-transferases. Biochem Pharmacol 35: 3404-3409, 1986.
3. Dulik DM and Fenselau C: Conversion of melphalan to 4-(glutathionyl) phenylalanine: a novel mechanism for conjugation by glutathione S-transferases. Drus Metab Dispos 15: 195-199, 1987.
4. Dulik DM, Colvin OM and Fenselau C: Characterisation of glutathione conjugates of chlorambucil by fast atom bombardment and thermospray liquid chromatography/mass spectrometry. Biomed Environ Mass Spectrom 19: 248-252, 1990.
5. Zhang K and Wong KP: Glutathione conjugation of chlorambucil: measurement and modulation by plant polyphenols. Biochem J 325: 417-422, 1997.
6. Gamcsik MP, Hamill TG and Colvin OM: NMR studies of conjugation of mechlorethamine with glutathione. J Med Chem 33: 1009-1014, 1990.
7. Yuan ZM, Smith PB, Brundrett RB, Colvin OM and Fcnselau C: Glutathione conjugation with phosphoramine mustard and cyclophosphamide, a mechanistic study using tandem mass spcctrometry. Drug Metab Dispos 19: 625-629, 1991.
8. Dirven HA, Vennekamp JC, van Ommen B and van Bladeren PJ: The interaction of glutathione with 4-hydroxycyclophosphamide and phosphoramide mustard studied by 31P nuclear magnetic resonance spectroscopy. Chem Biol Interact 93: 185-196, 1994.
9. Dirven HA, van Ommen B and van Bladeren PJ: Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res 54:6215-6220, 1994.
10. Dirven HA, Megens I, Oudshoorn MJ, Dingemanse MA, van Ommen B and van Bladeren PJ: Glutathione conjugation of cytostatic drug ifosfamide and the role of human glutathione S-transferases. Chem Res Toxicol 8: 979-986, 1995.
11. Ishikawa T and Ali-Osman F: Glutathione-associated cis-diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukaemia cells, molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 268: 20116-20125, 1993.
12. Dirven HAAM, Dictus ELJT, Brocders NLHL, van Ommen B and van Bladeren PJ: The role of human glutathione S-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thiotepa. Cancer Res 55: 1701-1706, 1995.
13. Smith MT, Evans CG, Doane-Setzer P, Castro VM, Tahir MK and Mannervik B: Denitrosation of 1,3-Bis(2-chloroethyl)-1-nitrosourea by class Mu GSTs and its role in cellular resistance in rat brain tumour cells. Cancer Res 49: 2621-2625, 1989.
14. Jenson DE and Stelman GJ: Evidence for cytosolic glutathione S-transferase-mediated denitrosation of nitrosocimetidine and 1-methyl-2-nitro-1-nitrosoguanidine. Carcinogenesis 8: 1791-1800, 1987.
15. Colvin OM, Friedman HS, Gamcsik MP, Fenselau C and Hilton J: Role of glutathione in cellular resistance to alkylating agents. Adv Enzyme Regul 33: 19-26, 1993.
16. Bolton MC, Colvin OM and Hilton J: Specificity of isoenzymes of murine hepatic glutathione S-transferases for the conjugation of glutathione with L-phenylalanine mustard. Cancer Res 51: 2410-2415, 1991.
17. Berhane K and Mannervik B: Inactivation of the genotoxic aldehyde acrolein by human glutathione transferases of class alpha, Mu and Pi. Mol Pharmacol 37: 251-254, 1989.
18. Rowley DA and Halliwell B: DNA damage by superoxide-generating systems in relation to the mechanism of action of the antitumor antibiotic adriamycin. Biochim Biophys Acta 761: 86-93, 1983.
19. Samuels BL, Murray JL, Cohen MB, Safa AR, Sinha BK, Townsend AJ, Beckett MA and Weichselbaum RR: Increased glutathione peroxidase activity in a human sarcoma cell line with inherent doxorubicin resistance. Cancer Res 51:521 -527, 1991.
20. Prohaska JR: The glutathione peroxidase activity of glutathione transferases. Biochim Biophys Acta 611: 87-98, 1980.
21. Pool M, Esterbauer H, Rabinovitch PS and Hoehn H: Disturbance of cell proliferation by two model compounds of lipid peroxidation contradicts causative role in proliferative senescence. J Cell Physiol 137: 421-429, 1988.
22. Tan KH, Meyer DJ, Gillies N and Ketterer B: Detoxification of DNA hydroperoxide by the glutathione transferases and the purification and characterization of glutathione transferases from rat liver nucleus. Biochem J 254: 841-845, 1988.
23. Commandeur JNM, Stijntjes GJ and Vermeulen PE: Enzymes and transport systems involved in the formation and disposition of glutathione S-conjugates. Pharmacol Rev 47: 271-330, 1995.
24. Ishikawa T: The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci 17: 463-468, 1992.
25. Kondo T, Sale GL and Beutler E: Glutathione transport by inside-out vecicles from human erythrocytes. Proc Natl Acad Sci USA 77: 6359-6362, 1980.
26. Kondo T, Yoshida K, Urata Y, Goto S, Gasa S and Taniguchi N: γ-glutamylcysteine synthetase and active transport of glutathione S-conjusate are responsive to heat shock in K 562 erythroid cells. J Biol Chem 268: 20366-20372, 1993.
27. Olive C and Board P: Glutathione S-conjugate transport by cultured human cells. Biochim Biophys Acta 1224: 264-268, 1994.
28. Zhang K and Wong KP: Active transport of glutathione conjugate in human colon adenocarcinoma cells. Cancer Lett 108: 143-151, 1996.
29. Rosenberg B: Fundamental studies with cisplatin. Cancer 55: 2303-2316, 1985.
30. Andrews PA, Murphy MP and Howell SB: Differential sensitization of human ovarian carcinoma and mouse L1210 cells to cisplatin and melphalan by GSH depletion. Mol Pharmacol 30: 643-650, 1986.
31. Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG: Relationship of cellular glutathione to the cytotoxicity and resistance to seven platinum compounds. Cancer Res 52: 6885-6889, 1992.
32. Richon VM, Schulte N and Eastman A: Multiple mechanisms of resistance to cis-diamminedichloroplatinum (II) in murine leukaemia L1210 cells. Cancer Res 47: 2056-2061, 1987.
33. Ishikawa T, Wright CD and Ishizuka H: GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum (II)-resistant human leukaemia HL-60 cells and down-regulated by cell differentiation. J Biol Chem 269: 29085-29093, 1994.
34. Goto S, Yashita K, Morikawa T, Urata Y, Suzuki K and Kondo T: Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells. Cancer Res 55: 4297-4301, 1995.
35. Keizer HG, Schuurhuis GJ, Broxterman HJ, Lankelma J, Schoonen WGEJ, van Riji J, Pinedo HM and Joenje H: Correlation of multidrug resistance with decreased accumulation, altered subcellular drug distribution and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res 49: 2988-2993, 1989.
36. Nielson D and Skovsgaard T: P-glycoprotein as a multidrug transporter: a critical review of current multidrug resistant cells. Biochim Biophys Acta 1139: 169-183, 1992.
37. Spoelstra EC, Westerhoff HV, Dekker H and Lankelma J: Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells. Eur J Biochem 207: 567-579, 1992.
38. Versantvoort CHM, Broxterman HJ, Pinedo HM, de Vries EGE, Feller N, Kuiper CM and Lankelma J: Energy-dependent processes involved in reduced drug accumulation in multidrug human lung cancer cell lines without P-glycoprotein expression. Cancer Res 52: 17-23, 1992.
39. Roepe PD: Analysis of steady-state and initial rate of doxorubicin efflux from a series of multidrug resistant cells expressing different levels of P-glycoprotein. Biochemistry 31: 12555-12564, 1992.
40. Awasthi S, Singhal SS, Srivastava SK, Zimniak P, Bajpai KK, Saxena M, Sharma R, Ziller SA, Frenkel EP, Singh SV, He NG and Awasthi YC: Adenosine triphosphate-dependent transport of doxorubicin, daunomycin and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein. J Clin Invest 93: 958-965, 1994.
41. Zimniak P, Awasthi S and Awasthi YC: Phase III detoxification system. Trends Biochem Sci 18: 164-165, 1993.
42. Murray GI, Burke MD and Ewen SW: Glutathione localisation in benign and malignant human breast lesions. Br J Cancer 55: 605-609, 1987.
43. Guichard M, Lespinasse F, Esterlin R, Gerbaulet A, Hie C, Lartigau E, Malaise EP, Micheau C, Prade M, Richard GM and Weeger P: Glutathione and cysteine levels in human tumour biopsies. Br J Radiol 63: 557-561, 1990.
44. Mickisch G, Fajta S, Bier H, Tschada R and Alken P: Cross-resistance patterns related to glutathione metabolism in primary human renal cell carcinoma. Urol Res 19: 99-103, 1991.
45. Blair SL, Heerdt P, Sachar S, Ablhoda A, Hochwald S, Cheng H and Burt M: Glutathione metabolism in patients with non-small cell lung cancers. Cancer Res 57: 152-155, 1997.
46. Rice GC, Bump EA, Shrieve DC, Lee W and Kovacs M: Quantitative analysis of cellular glutathione in Chinese hamster ovary cells by cytometry utilizing monochlorobimane: some applications to radiation and drug resistance in vitro and in vivo. Cancer Res 46: 6105-6110, 1986.
47. Lee FYF, Vessey AR and Siemman DW: Glutathione as a determinant in cellular response to adriamycin. NCI Monogr 6: 211-215, 1988.
48. Lee FYF, Siemann DW and Sutherland RM: Changes of cellular glutathione content during adriamycin treatment in human ovarian cancer: a possible indicator of chemosensitivity. Br J Cancer 60: 291-298, 1989.
49. Hatcher EL, Alexander JM and Kang YJ: Decreased sensitivity to adriamycin in cadmium-resistant human lung carcinoma A549 cells. Biochem Pharmacol 53: 747-754, 1997.
50. Ono K and Shrieve DC: Enhancement of EMT6/SF tumor cell killing by mitomycin C and cyclophosphamide following in vivo administration of buthionine sulfoximine. Int J Radiat Oncol Biol Phys 12: 1175-1178, 1986.
51. Xu BH, Cupta V and Singh SV: Mitomycin C sensitivity in human bladder cancer cells: Possible role of glutathione and glutathione transferase in resistance. Arch Biochem Biophys 308: 164-170, 1994.
52. Kramer RA, Greene K, Ahmad S and Vistica DT: Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulphoximine. Cancer Res 47: 1593-1597, 1987.
53. Yang WZ, Begleiter A, Johnston JB, Israels LG and Mowat MRA: Role of glutathione and glutathione transferase in chlorambucil resistance. Mol Pharmacol 41: 625-630, 1992.
54. Lutzky J, Astor MB, Taub RN, Baker MA, Bhalla K, Gervasoni JE, Rosoado M, Stewart V, Krishna S and Hindenberg AA: Role of glutathione and dependent enzymes in anthacycline-resistant HL60/AR cells. Cancer Res 49: 4120-4125, 1989.
55. Godwin AK, Meister A, O'Dwyer P, Huang CS, Hamilton TC and Anderson ME: High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89: 3070-3074, 1992.
56. Newkirk K, Heffern J, Sloman-Moll E, Sessions RB, Rasmussen AA, Andrews PA and Cullen KJ: Glutathione content but not gamma glutamylcysteine synthetase mRNA expression predicts cisplatin resistance in head and neck cancer cell lines. Cancer Chemother Pharmacol 40: 57-80, 1997.
57. Tanner B, Hengstler JG, Dietrich B, Henrich M, Steinberg P, Weikel W, Meinert R, Kaina B, Osech F, Knapstein PG: Glutathione, glutathione transferase alpha and pi and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer. Gynecol Oncol 65: 54-62, 1997.
58. Cheng X, Kigawa J, Minagawa, Y, Kanamori Y, Itamochi H, Okada M and Terakawa N: Glutathione S-transferase-pi expression and glutathione concentration in ovarian carcinoma before and after chemotherapy. Cancer 79: 521-527, 1997.
59. Britten RA, Green JA and Warenius HM: Cellular glutathione and glutathione S-transferases activity in human ovarian tumor biopsis following exposure to alkylating agents. Int J Radiat Oncol Biol Phys 24: 527-531, 1992.
60. Griffith OW: Mechanism of action, metabolism and toxicity of buthionine sulphoximine and its higher homologs, potent inhibitor of glutathione synthesis. J Biol Chem 257: 13704-13712, 1982.
61. Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM and Ozols RF: Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 44: 5427-5431, 1984.
62. Hamilton TC, Winber MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, Mckoy WM, Young RC and Ozols RF: Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and sensitive human ovarian carcinoma cell lines by buthionine sulphoximine mediated glutathione depletion. Biochem Pharmacol 34: 2583-2586, 1985.
63. Dusre L, Mimnaugh EG, Myers CE and Sinha BK: Potentiation of doxorubicin cytotoxicity by buthionine sulphoximine in multidrug resistant human breast tumor cells. Cancer Res 49: 511-515, 1989.
64. Mans DRA, Schuurhuis GJ, Treskes M, Lafleur MVM, Retel J, Pinedo HM and Lankelma J: Modulation of buthionine sulphoximine of etoposide cytotoxicity on human non-small cell lung, ovarian and breast carcinoma cell lines. Eur J Cancer 28A: 1447-1452, 1992.
65. Schneider E, Yamazaki H, Sinha BK and Cowan KH: Buthionine sulphoximine-mediated sensitisation of etoposide-resistant human breast cancer MCF7 cells overexpressing the multidrug resistance-associated protein involves increased drug accumulation. Br J Cancer 71: 738-743, 1995.
66. Jensson H, Eriksson LC and Mannervik B: Selective expression of glutathione transferase isoenzymes in chemically induced preneoplastic rat hepatocyte nodules. FEBS Lett 187: 115-120, 1987.
67. Farber E: The biochemistry of preneoplastic liver: a common metabolic pattern in hepatocyte nodules. Biochem Cell Biol 62: 486-494, 1988.
68. Sato K: Glutathione S-transferases and hepatocarcinogenesis. Jpn J Cancer Res 79: 566-572, 1988.
69. Sato K: Glutathione S-transferases as markers of preneoplasia and neoplasia. Adv Cancer Res 52: 205-255, 1989.
70. Mannervik B, Gastro VM, Danielson UH, Kalim Tabir M, Hansson J and Ringberg U: Expression of class pi glutathione transferase in human malignant melanoma cells. Carcinogenesis 8: 1929-1932, 1987.
71. Peters WHM, Nagengast FM and Wobbers T: Glutathione S-transferases in normal and cancerous human colon. Carcinogenesis 10: 2371-2374, 1990.
72. Clapper ML, Hoffman SK and Tew KD: Glutathione S-transferases in normal and malignant human colon tissue. Biochim Biophys Acta 1096: 209-216, 1991.
73. Sato K, Satoh K, Hatayama I, Tsuchida S, Soma Y, Shiratori Y, Tateoka N, Inaba Y and Kitahara A: Placental glutathione S-transferase as a marker for preneoplastic tissues. In: Glutathione S-transferases and Carcinogenesis. Mantle TJ, Pickett CB and Hayes JD (eds.) Taylor and Francis, London, pp127-137, 1987.
74. Howie AF, Forrester LM, Glancey MJ, Schlager JJ, Powis G, Backett GH, Hayes JD and Wolf CR: Glutathione S-transferases and glutathione peroxidase expression in human normal and tumor tissue. Carcinogenesis 11: 451-458, 1990.
75. Jungnelius U, Hao XY, Skog S, Castro VM, Mannervik B and Ringberg U: Cell cycle dependent sensitivity of human melanoma cells to melphalan is correlated with activity and cellular concentration of glutathione transferases. Carcinogenesis 15: 99-103, 1994.
76. Schisselbauer JC, Silber R, Papadopoulos E, Abrams K, LaCreta FP and Tew KD: Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukaemia patients. Cancer Res 50: 3562-3568, 1990.
77. Lewis AD, Hayes JD and Wolf CR: Glutathione and glutathione dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. Carcinogenesis 9: 1282-1287, 1988.
78. Lewis AD, Hickson ID, Robson CN, Harris AL, Hayes JD, Griffiths SA, Manson MM, Hall AE, Moss JE and Wolf CR: Amplification and increased expression of alpha class glutathione S-transferase-encoding genes associated with resistance to nitrogen mustards. Proc Natl Acad Sci USA 85: 8511-8515, 1988.
79. Cole SP, Downes HF, Mirski SE and Clements DJ: Alternations on glutathione and glutathione-related enzymes in a multidrug-resistant small cell lung cancer cell line. Mol Pharmacol 37: 192-197, 1990.
80. Okuyama T, Maehara Y, Endo K, Baba H, Adachi Y, Kuwano M and Sugimachi K: Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin. Cancer 74: 1230-1236, 1994.
81. Miyamoto KI, Wakabayashi D, Minamino T and Nomura M: Glutathione S-transferase P-form dependent chlorambucil resistance in Yoshida rat ascites hepatoma cell lines. Cancer Lett 78: 77-83, 1994.
82. Sharma R, Singhal SS, Srivastava SK, Bajpai KK, Frenkel EP and Awasthi S: Glutathione and glutathione-linked enzymes in human small cell lung cancer cell lines. Cancer Lett 75: 111-119, 1993.
83. Kotoh S, Naito S, Yokomizo A, Kohno K, Kuwano M and Kumazawa J: Enhanced expression of gamma-glutamylcysteine synthetase and glutathione S-transferase genes in cisplatin-resistant cancer cells with multidrug resistance phenotype. J Urol 157: 1054-1058, 1997.
84. Black SM, Beggs JD, Hayes JD, Batoszek A, Muramatsu M, Sakai M and Wolf CR: Expression of human glutathione S-transferases in Saccharomyces cerevisiae confers resistance to anticancer drugs adriamycin and chlorambucil. Biochem J 268: 309-315, 1990.
85. Puchalski RB and Fahl WE: Expression of recombinant glutathione transferase Ya, or YbI confers resistance to alkylating agents. Proc Natl Acad Sci USA 87: 2443-2447, 1990.
86. Miyazaki M, Kohno K, Saburi Y, Matsuo K-I, One M, Kuwano M, Tsuchida S, Sato K, Sakai M and Muramatsu M: Drug resistance to cis-diamminedichloroplatinum (II) in Chinese hamster ovary cell lines transfected with glutathione S-transfcrase Pi gene. Biochem Biophys Res Commun 166: 1358-1364, 1990.
87. Nakagawa K, Saijo N, Tsuchida S, Sakai M, Tsunokawa Y, Yokota J, Muramatsu M, Sato K, Terada M and Tew KD: Glutathione S-transferase as a determinant of drug resistance in transfectant cell lines. J Biol Chem 265: 4296-4301, 1990.
88. Leyland-Jones BR, Townsend AJ, Tu C-PD, Cowan KH and Goldsmith ME: Anti-neoplastic drug sensitivity of human MCF-7 breast cancer cells stably transfected human alpha-class glutathione S-transfcrase gene. Cancer Res 51: 587-594, 1991.
89. Manoharan TH, Welch PJ, Gulick AM, Puchalski RB, Lathrop AL and Fahl WE: Expression of tandem glutathione S-transferase recombinant genes in COS cells for analysis of efficiency of protein expression and associated drug resistance. Mol Pharmacol 39: 461-467, 1991.
90. Miyara H, Hida T, Nishida K, Takahashi T, Sugiura T, Ariyoshi Y, Morishita M, Takahashi T and Ueda R: Modification of chemo-radiosensitivity of a human lung cancer cell line by introduction of the glutathione S-transferase pi gene. Jpn J Clin Oncol 26: 1-5, 1996.
91. Ploemen JHTM, van Ommen B and van Bladeren PJ: Inhibition of rat and human glutathione S-transferase isoenzymes by ethacrynic acid and its glutathione conjugate. Biochem Pharmacol 40: 1631-1635, 1990.
92. f. Evidence for an allosteric site for ethacrynic acid. Biochem J 275: 703-709, 1991.
93. Tew KD, Bomber AM and Hoffman SJ: Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res 48: 3622-3625, 1988.
94. Hansson J, Berhane K, Gastro VM, Jungnelius U, Mannervik B and Ringberg U: Sensitization of human melanoma cells to the cytotoxic effect of melphalan by the glutathione S-transferase inhibitor ethacrynic acid. Cancer Res 51: 94-98, 1991.
95. Clapper ML, Hoffman SK and Tew KD: Sensitisation of human colon tumor xenografts to L-phenylalanine mustard using ethacrynic acid. J Cell Pharmacol 1: 71-78, 1990.
96. Chen G and Waxman DJ: Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells. Biochem Pharmacol 49: 1691-1701, 1995.
97. O'Dwyer PJ, LaCreta F, Nash S, Tinsley PW, Schider R, Clapper ML, Tew KD, Panting L, Litwin S, Comis RL and Ozols RF: Phase I Study of thio-TEPA in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res 51: 6059-6065, 1991.
98. LaCreta FP and Brennan JM: Effects of ethacrynic acid and SKF 525A on hepatic thio-TEPA elimination. Proc Am Assoc Cancer Res 32: 339-348, 1991.
99. Zhang K and Das NP: Inhibitory effects of plant polyphenols on rat liver glutathione S-transferases. Biochem Pharmacol 47: 2063-2068, 1994.
100. Zhang K, Mack P and Wong KP: Inhibition of various isoforms of rat liver glutathione S-transferases by tannic acid and butein. Biochem Mol Biol Internal 42: 701-710, 1997.
101. Kuhnau J: The flavonoids: a class of semi-essential food components: The role in human nutrition. World Rev Nutr Diet 24: 117-121, 1976.
102. Haslam E, Lilley TH, Ya C, Martin R and Magnoato D: Traditional herbal medicine. The role of polyphenols. Planta Med 55: 1-8, 1985.
103. Yugarani T, Tan BKH, Teh M and Das NP: Effects of polyphenolic natural products on lipid profiles of rat fed high fat diets. Lipids 27: 181-186, 1992.
104. Kikuchi Y, Hirata J, Yamamoto K, Ishii K, Kita T, Kudoh K, Tode T, Nagata I, Tanguchi K and Kuwano M: Altered expression of gamma-glutamylcysteine synthetase, metallothionein and topoisomerase I and II during acquisition of drug resistance to cisplatin in human ovarian cancer cells. Jpn J Cancer Res 88: 213-217, 1997.
105. Yao KS, Godwin AK, Johnson SW, Ozols RF, O'Dwyer PJ and Hamilton TC: Evidence for altered regulation of gamma-glutamylcysteine gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res 55: 4367-4374, 1995.
106. Kurokawa H, Ishida T, Nishio K, Arioka H, Sata M, Fukumoto H, Miura M and Saijo N: Gamma-glutamylcysteine synthetase gene expression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. Biochem Biophys Res Commun 216: 258-264, 1995.
107. Kurokawa H, Nishio K, Ishida T, Arioka H, Fukuoka K, Nomoto T, Fukumoto H, Yokote H and Saijo N: Effect of glutathione depletion on cisplatin-resistance in cancer cells transfected with the gamma-glutamylcysteine synthetase gene. Jpn J Cancer Res 88: 108-110, 1997.
108. Lai GM, Moscow JA, Alvorez MG, Fojo AT and Bate SE: Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines. Int J Cancer 49: 688-695, 1991.
109. Benchekroun MN, Pourquier P, Schott B and Robert J: Doxorubicin-induced lipid peroxidation and glutathione peroxidase activity in tumor cell lines selected for resistance to doxorubicin. Eur J Biochem 211: 141-146, 1993.
110. Ogawa J, Iwazaki M, Inoue H, Koide S and Shohtsu A: Immunohistochemical study of glutathione-related enzymes and proliferative antigens in lung cancer. Relation to cisplatin sensitivity. Cancer 71: 2204-2209, 1993.
111. Hao XY, Bergh J, Brodin O, Hellman U and Mannervik B: Aquired resistance to cisplatin and doxorubicin in a small cell lung cancer cell line is correlated to elevated expression of glutathione-linked detoxification enzymes. Carcinogenesis 15: 1167-1173, 1994.
112. Colinas RJ, Hunt DH, Walsh AC and Lawrence DA: Hydroquinone resistance in a murine myeloblastic leukemia cell line. Involvement of quinone reductase and glutathione-dependent detoxification in nonclassical multidrug resistance. Biochem Pharmacol 52: 945-956, 1996.
113. Zhang K, Yang EB, Tang WY, Wong KP and Mack P: Inhibition of glutathione reductase by plant polyphenols. Biochem Pharmacol 54: 1047-1053, 1997.
114. Mestdagh N, Morier-Teissier E and Henichart JP: Effect of various chemosensitizers on chemoresistance to adriamycin in MIP-101 cell line, a colon carcinoma cell line: analysis of glutathione and related enzymes. Anticancer Drugs 4: 641-650, 1993.
115. Vanhoefer U, Yin MB, Harstrick A, Seeber S and Rustum YM: Carbamoylation of glutathione reductase by N,N-bis(2-chloroethy)-N-nitrosourea associated with inhibition of multidrug resistance protein (MRP) function. Biochem Pharmacol 53: 801-809, 1997.
116. Zaman GJR, Flens MJ, van Leusden MR, de Haas M, Mulder HS, Lankelma J, Pinedo HM, Scheper RJ, Broxterman HJ and Borst P: The human multidrug resistance-associated protein MRP is a plasma membrane drug efflux pump. Proc Natl Acad Sci USA 91: 8822-8826, 1994.
117. Cole SPC, Bhardawaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AWV and Deeley RG: Overexpression of a novel transporter gene in a multidrug resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
118. Krishnamachary N and Center MS: The MRP gene associated with non P-glycoprotein multidrug resistance encodes a 190 K Dalton membrane bound protein. Cancer Res 53: 3658-3661, 1993.
119. Slovak ML, Ho J, Deeley RG and Cole SPC: Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69/AR human tumor cell lines. Cancer Res 53: 3221-3225, 1993.
120. Zaman GJR, Versantvoort CHM, Smit JJM, Eijdems EWHM, de Haas M, Smith AJ, Broxterman HJ, Mulder NH, de Vries EGE, Baas F and Borst P: Analysis of the expression of MRP, the gene for new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 53: 1747-1750, 1993.
121. Barrand MA, Heppel-Parton AC, Wright KA, Rabbits PH and Twentyman PR: A 190k protein overexpressed in non-P-glycoprotein containing MDR cells and its relation to the MRP gene. J Natl Cancer Inst 86: 110-117, 1994.
122. Ross DD, Doyle LA, Schiffer CA, Lee ET, Grant CE, Cole SPC, Deeley RG, Yang W and Tong Y: Expression of multidrug resistance-associated protein mRNA in blast cells from acute myeloid leukaemia patients. Leukemia 10: 48-55, 1996.
123. Grant CE, Valdimarsson G, Hipfner E, Almquist KC, Cole SPC and Deeley RG: Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54: 357-361, 1994.
124. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kur G and Keppler D: Transport of glutathione, glucuronate and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 56: 988-994, 1996.
125. Berger W, Hauptmann E, Elbling L, Vetterlein M, Kokoschka EM and Micksche M: Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells. Int J Cancer 71: 108-115, 1997.
126. Awasthi YC, Singhal SS, Gupta S, Ahmad H, Zimniak P, Radominska A, Lester R and Sharma R: Purification and characterization of an ATPase from human liver which catalyse ATP hydrolysis in the presence of the conjugates of bilirubin, bile acid and glutathione. Biochem Biophys Res Commun 175: 1090-1096, 1991.
127. Saxena M, Singhal SS, Awasthi S, Singh SV, Labelle EF, Zimniak P and Awasthi YC: Dinitrophenyl S-glutathione ATPase purified from human muscle catalyses ATP hydrolysis in the presence of leukotrienes. Arch Biochem Biophys 298: 231-237, 1992.
128. Leier I, Jedlitschky G, Buchholz U and Keppler D: Characterization of the ATP-dependent leukotriene C4 export carrier in mastocytoma cells. Eur J Biochem 220: 599-606, 1994.
129. Leier I, Jedlitschky G, Buchholz, U, Cole SPC, Deeley RG and Keppler D: The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 269: 27807-27810, 1994.
130. Keppler D, Leier I and Jedlitschky G: Transport of glutathione conjugate and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol Chem 378: 787-791, 1997.
131. Loe DW, Steward RK, Massey TE, Deeley RG and Cole SP: ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol Pharmacol 51: 1034-1041, 1997.
132. Muller M, Meijer C, Zaman GJR, Borst P, Scheper RJ, Mulder NH, de Vries EGE and Janson PLM: Overexpression of the gene encoding the multidrug resistance associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 91: 13033-13037, 1994.
133. Akerboom TP, Narayanaswami V, Kunst M and Sies H: ATP-dependent S-(2,4-dinitrophenyl)glutathione transport in canalicular plasma membrane vesicles from rat liver. J Biol Chem 266: 13147-13152, 1991.
134. Kobayashi K, Sogame Y, Hara H and Hayashi K: Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membrane. J Biol Chem 265: 7737-7741, 1990.
135. Clifford SC, Neal DE and Lunec T: Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high grade transitional cell carcinoma of the bladder. Br J Cancer 73: 659-666, 1996.
136. Versantvoort CHM, Broxterman HJ, Bagrij T, Scheper RJ and Twentyman PR: Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines over-expressing multidrug resistance-associated protein. Br J Cancer 72: 82-89, 1995.
137. Zaman GJR, Lankelma J, van Tellingen O, Beijnen J, Dekker H, Pauluama C, Oude-Elferink RPJ, Baas F and Borst P: Role of glutathione in the export of compounds from cells by the multi-drug resistance-associated protein. Proc Natl Acad Sci USA 92: 7690-7694, 1995.
138. Shen H, Paul S, Breuninger LM, Ciaccio PJ, Laing NM, Helt M, Tew KD and Kruh GD: Cellular and in vitro transport of glutathione conjugate by MRP. Biochemistry 35: 5719-5725, 1996.
139. 4 and chemotherapeutic agents in membrane vesicles. J Biol Chem 271: 9675-9682, 1996.
140. Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
141. Jonsson K, Dahlberg N, Tidefelt U, Paul C and Andersson G: Characterization of an anthracycline-resistant human promyelocyte leukemia cell line (HL-60) with an elevated MDR-I gene expression. Biochem Pharmacol 49: 755-762, 1995.
142. Ishikawa T: Is the glutathione S-conjueate carrier an mdr-1 gene product? Trends Biochem Sci 15: 219-220, 1990.
143. Bradley G, Juranka PF and Ling V: Mechanisms of multidrug resistance. Biochim Biophys Acta 948: 87-128, 1988.
144. Endicott JA and Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171, 1989.
145. Jedlitschky G, Leier I, Buchholz U, Center M and Keppler D: ATP-dependent transport of glutathione S-conjugates by the multi-drug resistance-associate protein. Cancer Res 54: 4833-4836, 1994.
146. Versantvoort CHM, Schuurhuis GJ, Pinedo HM, Eekman CA, Kuiper CM, Lankelma J and Broxterman HJ: Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer 68: 939-946, 1993.
147. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM and Deeley RG: Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902-5910, 1994.
148. Barrand MA, Bagrij T and Neo SY: Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion. Gen Pharmacol 28: 639-645, 1997.
149. Ford JM and Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199, 1990.
150. Keller RP, Altermatt HJ, Donatsch P, Zihlmann P, Laissue JA and Hiestand PC: Pharmacologic interactions between the resistance-modifying cyclosporin SDZ PSC 833 and etoposide (VP 16-123) enhance in vivo cytostatic activity and toxicity. Int J Cancer 51: 433-438, 1992.
151. Watanabe T, Tsuge H, Oh-Hara T, Naito M and Tsuruo T: Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 34: 235-241, 1995.
152. Barrand MA, Rhodes T, Center MS and Twentyman PR: Chemosensitization and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer 29A: 408-415, 1993.
153. Beck J, Niethammer D and Gekeler V: High MDR1 and MRP but low topoisomerase II gene expression in B-cell chronic lymphocytic leukaemia. Cancer Lett 86: 135-142, 1994.
154. Beck J, Handgretinger R, Dopfer R, Klingebiel T, Niethammer D and Gekeler V: Expression of MDR1, MRP, topoisomerase II alpha/beta and cyclin A in primary or relapsed states of acute lymphoblastic leukaemia. Br J Haematol 89: 356-363, 1995.
155. Gekeler V, Beck J, Noller A, Wilisch A, Frese G, Neumann M, Handgretinger R, Ehninger G, Probst H and Niethammer D: Drug-induced changes in the expression of MDR-associated genes: investigation on cultured cell lines and chemotherapeutically treated leukaemias. Ann Hematol 69: S19-S24, 1994.
156. Chuman Y, Sumizawa T, Takebayashi Y, Niwa K, Yamada K, Haraguchi M, Furukawa T, Akiyama S and Aikou T: Expression of the multidrug-resistance-associated protein (MRP) gene in human colorectal, gastric and non-small-cell lung carcinomas. Int J Cancer 66: 274-279, 1996.
157. Ross DD, Doyle LA, Schiffer CA, Lee EL, Grant CE, Cole SP, Deeley RG, Yang W and Tong Y: Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients. Leukemia 10: 48-55, 1996.
158. Meijer C, Mulder NH, Timmer-Bosscha H, Peters WHM and de Vries EGE: Combined in vitro modulation of adriamycin resistance. Int J Cancer 49: 582-586, 1992.
159. Chambers TC, Zheng B and Kuo JF: Regulation by phorbol ester and protein kinase C inhibitors, and by protein phosphatase inhibitor (okadaic acid) of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug resistant human KB cells. Mol Pharmacol 41: 1008-1015, 1992.
160. Ma L, Marquardt D, Takemoto L and Center MS: Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine. J Biol Chem 266: 5593-5599, 1991.
161. Ma L, Krishnamachary N and Center MS: Phosphorylation of the multidrug resistance associated protein gene encoded protein P190. Biochemistry 34: 3338-3342, 1995.
162. Zhang K and Wong KP: Inhibition of the efflux of glutathione S-conjugate by plant polyphenols. Biochem Pharmacol 52: 1631-1638, 1996.
163. Gekeler V, Boer R, Ise W, Sanders KH, Schachtele C and Back J: The specific bisindolylmaleimide PKC-inhibitor GF 109203X efficiently modulates MRP-associated multidrug resistance. Biochem Biophys Res Commun 206: 119-126, 1995.
164. Gekeler V, Ise W, Sanders KH, Ulrich WR and Back J: The leukotriene LTD4 recepter antagonist MK 571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 208: 345-352, 1995.
165. Sumizawa T, Chen ZS, Chuman Y, Seto K, Furukawa T, Haraguchi M, Tani A, Shudo N and Akiyama SI: Reversal of multidrug res̀istance-associated protein-mediated drug resistance by the pyridine analog PAK-104P. Mol Pharmacol 51: 399-405, 1997.
166. Endo K, Maehara Y, Ichiyashi Y, Kusumoto T, Sakaguchi Y, Ohno S and Sugimachi K: Multidrug resistance-associated protein expression in clinical gastric carcinoma. Cancer 77: 1681-1687, 1996.
167. Stewart AJ, Canitrot Y, Baracchini E, Dean NM, Deeley RG and Cole SPC: Reduction of expression of multidrug resistance protein (MRP) in human tumor tissue cells by antisence phosphorothionate oligoneucleotides. Biochem Pharmacol 51: 461-469, 1996.
168. Jain N, Lam YM, Pym J and Campling BG: Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Cancer 77: 1797-1808, 1996.